Trial record 1 of 1 for:
OBS13436
LEMTRADA Pregnancy Registry in Multiple Sclerosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03774914 |
|
Recruitment Status :
Terminated
(The sponsor stopped the study due to low recruitment with no safety concerns)
First Posted : December 13, 2018
Last Update Posted : April 25, 2022
|
Sponsor:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Primary Objective:
The primary goal of this registry is to assess the risk of spontaneous abortion in prospective enrolled women exposed to LEMTRADA for multiple sclerosis.
Secondary Objective:
The secondary goals of this registry is to assess maternal, fetal and infant outcome in women with multiple sclerosis, exposed to LEMTRADA.
| Condition or disease | Intervention/treatment |
|---|---|
| Multiple Sclerosis | Drug: Alemtuzumab (GZ402673) |
| Study Type : | Observational [Patient Registry] |
| Actual Enrollment : | 42 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Target Follow-Up Duration: | 20 Months |
| Official Title: | International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis |
| Actual Study Start Date : | September 1, 2015 |
| Actual Primary Completion Date : | November 22, 2021 |
| Actual Study Completion Date : | November 22, 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Multiple sclerosis
Drug Information available for:
Alemtuzumab
| Group/Cohort | Intervention/treatment |
|---|---|
|
Lemtrada
Pregnant women exposed to LEMTRADA which is administered by IV infusion for 5 consecutive days, then for 3 consecutive days, 12 months after the first/previous treatment course
|
Drug: Alemtuzumab (GZ402673)
Pharmaceutical form:Concentrate for solution for infusion Route of administration: Intravenous infusion
Other Name: Lemtrada |
Primary Outcome Measures :
- Spontaneous abortions (≤20 weeks gestation) [ Time Frame: 32 weeks gestation ]Number and rate of spontaneous abortions on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
Secondary Outcome Measures :
- Major congenital malformations [ Time Frame: From birth to 1 year after delivery ]Numbers and rates of major congenital malformations on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Minor congenital malformations [ Time Frame: From birth to 1 year after delivery ]Numbers and rates of minor congenital malformations on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Stillbirth (any non-deliberate foetal death at >20 weeks gestation) [ Time Frame: 26-32 weeks' gestation to within 6 weeks after the end of the pregnancy ]Numbers and rates of stillbirth, on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Full-term live birth i.e. infants born maturely (≥37 gestation weeks) [ Time Frame: Within 6 weeks after the end of the pregnancy ]Numbers and rates of full-term live birth on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Preterm birth i.e. infants born prematurely i.e., live-born infant i.e., (pre-term <37 weeks) [ Time Frame: 26-32 weeks' gestation to within 6 weeks after the end of the pregnancy ]Numbers and rates of pre-term birth on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Elective terminations i.e. any induced or voluntary fetal loss [ Time Frame: 16-20 weeks' gestation ]Numbers and rates of elective terminations on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Small for gestational age at birth i.e. birth size (weight, length, or head circumference) ≤10th percentile for gender and gestational age [ Time Frame: Within 6 weeks after the end of the pregnancy ]Numbers and rates of small for gestational age on pregnant women prospectively enrolled (pregnancy outcome unknown at time of enrollment)
- Any other adverse pregnancy outcomes [ Time Frame: Baseline to week 40 ]Numbers of adverse events
- Infant postnatal growth (up to the first year of life) [ Time Frame: 1 year after delivery ]Numbers and rates of infants with postnatal size (weight, length or head circumference) less than or equal to the 10th percentile for sex and age using National Center for Health Statistics (NCHS) pediatric growth curves, and adjusted postnatal age for premature infants.
- Infant development impairment (up to the first year of life) [ Time Frame: 1 year after delivery ]Numbers and rates of infants with development impairment
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Women with Multiple Sclerosis who were or became pregnant within the period of time between the first infusion of a course of treatment with LEMTRADA to 4 months after their last infusion for that course.
Criteria
Inclusion criteria :
- Women with Multiple Sclerosis who were or became pregnant within the period of time between the first infusion of a course of treatment with LEMTRADA to 4 months after their last infusion for that course.
- Women able and willing to provide informed consent for study participation and the requirement of the study. Informed consent will be obtained at the time of enrollment in accordance with local regulatory requirements.
Exclusion criteria:
- Previous enrollment in this study for a previous pregnancy.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03774914
Locations
| United States, New York | |
| Investigational Site Number :840999 | |
| New York, New York, United States, 00000 | |
| Australia, Victoria | |
| Investigational Site Number :036001 | |
| Box Hill, Victoria, Australia, 3128 | |
| Austria | |
| Investigational Site Number :040-001 | |
| Linz, Austria | |
| Belgium | |
| Investigational Site Number :56 | |
| Charleroi, Belgium, 6000 | |
| Canada | |
| Investigational Site Number :124999 | |
| Canada, Canada | |
| Denmark | |
| Investigational Site Number :208001 | |
| Aarhus C, Denmark, 8000 | |
| Germany | |
| Investigational Site Number :276001 | |
| Bochum, Germany, 44791 | |
| Italy | |
| Investigational Site Number :380001 | |
| Gallarate (VA), Italy, 21013 | |
| Netherlands | |
| Investigational Site Number :528999 | |
| Netherlands, Netherlands | |
| Spain | |
| Investigational Site Number :724999 | |
| Spain, Spain | |
| Sweden | |
| Investigational Site Number :752001 | |
| Göteborg, Sweden, 41345 | |
| Switzerland | |
| Investigational Site Number :756001 | |
| Zürich, Switzerland, 8091 | |
| United Kingdom | |
| Investigational Site Number :826-001 | |
| Salford, United Kingdom, M6 8HD | |
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
| Study Director: | Clinical Sciences & Operations | Sanofi |
Additional Information:
| Responsible Party: | Genzyme, a Sanofi Company |
| ClinicalTrials.gov Identifier: | NCT03774914 |
| Other Study ID Numbers: |
OBS13436 EU PAS - cat 3 |
| First Posted: | December 13, 2018 Key Record Dates |
| Last Update Posted: | April 25, 2022 |
| Last Verified: | April 21, 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Multiple Sclerosis Sclerosis Pathologic Processes Demyelinating Autoimmune Diseases, CNS Autoimmune Diseases of the Nervous System Nervous System Diseases |
Demyelinating Diseases Autoimmune Diseases Immune System Diseases Alemtuzumab Antineoplastic Agents, Immunological Antineoplastic Agents |